Natalie McNamee

Natalie McNamee

Private Equity Investor bei Tarnagulla Ventures Pty Ltd.

Consumer Services
Health Technology
Finance

Profil

Natalie has been a Director of Tarnagulla Ventures Pty Ltd since 2015.
She had led the investment diligence into most of the portfolio companies since then, including Lubris BioPharma, a company which has since successfully licensed their lead indication to Novartis.
Prior to returning to Australia, Natalie worked for Tocagen Inc, a gene therapy company, based in San Diego, in their business development team whilst finishing her Masters.
She then worked as a bioengineer at the then-newly formed Quanticel Pharmaceuticals, a cancer stem cell focused drug developer.
Quanticel was acquired by Celgene for $485M in 2015.
Natalie received her Masters in Bioengineering at UC San Diego and a dual Bachelor of Finance and Mechanical Engineering from Melbourne University.

Aktive Positionen von Natalie McNamee

UnternehmenPositionBeginn
Private Equity Investor 01.01.2015
Alle aktiven Positionen von Natalie McNamee

Ehemalige bekannte Positionen von Natalie McNamee

Ausbildung von Natalie McNamee

University of California San Diego Graduate Degree
University of Melbourne Undergraduate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Natalie McNamee im Detail an

Beziehungen

1

Beziehungen ersten Grades

4

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen2

Health Technology

Finance

Sehen Sie sich die Unternehmensverbindungen an
  1. Börse
  2. Insiders
  3. Natalie McNamee